These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16728567)

  • 1. Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
    Labrie F
    Endocr Relat Cancer; 2006 Jun; 13(2):335-55. PubMed ID: 16728567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
    Labrie F
    Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):584-93. PubMed ID: 17643129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
    Labrie F; Luu-The V; Labrie C; Simard J
    Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHEA, important source of sex steroids in men and even more in women.
    Labrie F
    Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is dehydroepiandrosterone a hormone?
    Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
    J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of the new selective estrogen receptor modulators.
    Palacios S
    Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
    Saji S; Kuroi K
    Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer.
    Fuqua SA; Russo J; Shackney SE; Stearns ME
    Postgrad Med; 2001 Mar; Spec No():3-10. PubMed ID: 11296736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tamoxifen and breast cancer].
    Nechushtan H; Peretz T
    Harefuah; 2002 Aug; 141(8):718-20, 761, 760. PubMed ID: 12222137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
    Labrie F
    J Steroid Biochem Mol Biol; 2015 Jan; 145():133-8. PubMed ID: 24923731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-reducing strategies for breast cancer--a review of recent literature.
    Mokbel K
    Int J Fertil Womens Med; 2003; 48(6):274-7. PubMed ID: 15646397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
    Jordan VC; O'Malley BW
    J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SERM--selective estrogen receptor modulators].
    Kønig KB; Eiken PA; Schwarz P
    Ugeskr Laeger; 2001 Apr; 163(15):2129-33. PubMed ID: 11332210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.